Nine patients with primary degenerative dementia (PDD) participated in an open trial of transdermal physostigmine (TPh). In order to evaluate the neurophysiologic effects of TPh, EEG data were recorded and compared at baseline and following 2 months of continuous treatment. There was no significant effect of TPh on EEG spectra in patients with PDD. © 1993 Rapid Communications of Oxford Ltd.
CITATION STYLE
Neufeld, M. Y., Mawassi, F., Levy, A., Treves, T. A., & Korczyn, A. D. (1993). Transdermal physostigmine—absence of effect on topographic brain mapping. Behavioural Neurology, 6(1), 33–35. https://doi.org/10.1155/1993/892685
Mendeley helps you to discover research relevant for your work.